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Introduction :
Palliative Pain Management 
Current Practice : 
Opioids 
The current first-line analgesic for moderate to severe
cancer pain is oral morphine recommended by the
World Health Organisation (WHO).5 Morphine is
extracted from opium which is the resin derived from
poppy sap. It has been recommended by WHO as a
treatment for cancer related pain since 1980.6
Morphine has the benefit of having a short half-life,
allowing frequent dose adjustments.5 Morphine doses
can range from 10mg-150mg per dose and is usually
delivered every four hours.6 This flexibility allows a
palliative care team to closely monitor a patient’s
condition and tailor the dose to suitably manage
chronic cancer pain. Morphine has a low cost, 100ml of
morphine sulphate with 2mg of morphine per 1ml
costs the NHS £2.01.7 Morphine is also readily
available5 making it a natural choice for treating
chronic palliative cancer pain.
However, opioid analgesics have the potential to cause
side effects such as nausea, vomiting, respiratory
distress, itching and constipation. When using
morphine to treat chronic pain as a long-term therapy,
dose escalation may be necessary if the patient
develops tolerance to the opioid.6
The current practice for moderate to severe pain
management is that morphine or codeine are typically
prescribed as the first-line treatment however, this is
not due to any pharmacological rationale. The
prescriber should then be prepared to switch
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Conclusion :
Combination Therapy
The most exciting application found in current research is
the outcome of combination opioid and cannabinoid
therapy. Studies have shown that the interactions of
opioids and cannabinoids may have an additive or
synergistic antinociceptive effect when used in
combination therapy. The practical application of this may
allow for reduced doses which could reduce side effects
while achieving satisfactory pain relief in palliation.15 This
potentially indicates that cannabinoids can be used to
reduce opioid dependence and tolerance.16 If this therapy
proves to be achievable it could result in an acute
improvement to the quality of life for palliative patients.
Recommendations :
Standardized Measure 
When assessing current research for this poster it became
clear that there isn’t a current standard measure for pain
or for the efficacy of analgesics. The European Palliative
Care Research Collaborative project brought to attention
the fact that the lack of consensus on the method used to
assess and classify cancer pain. This has led to difficulties
comparability in this area of research.2
A standardised system of measurement, while complex to
establish, for something as subjective as pain, would be
useful in validating results produced by studies. It could
help us move away from using opioids as a first line
treatment because of their familiarity but instead use
them based on evidence. It would increase the efficiency
of approval of new analgesic drugs, like cannabinoids.
Treatment plans would then be evidence based to provide
the most effective treatment for the management of
chronic cancer related pain in palliative patients.
Pain is a sensation that originates from ongoing tissue
damage.1 For palliative cancer patients this damage
arises from tumour growth and spread. Up to 70-80%
of patients with advanced cancer experience moderate
to severe pain. It has also been shown that many of
these patients do not receive adequate pain relief 2
with 50% of cancer patients pain being undertreated.3
In a comprehensive palliative care plan the
management of pain is one of the essential elements.4
Controlling the patient’s pain level in palliative stages
of the disease can improve the quality of life for the
patient and help families and carers with the end of life
process.
Individualised treatment of chronic pain should
balance the burden of the side effects with the
management of the pain.4 The optimum balance of
pain relief and maintaining a high quality of life is hard
to achieve. Here we examine the current practice for
pain palliation and how cannabis/cannabinoids may be
used in the future to aid palliative care.
Figure 1. Mechanism of action for THC11
Cannabinoids are derived from the resin produced by
the cannabis sativa plant. At least 60 active components
are found in cannabis.9 Studies have shown that
tetrahydrocannabinol: cannabidiol (THC:CBD) extract is
efficacious in the management of pain in advanced
cancer patients which is not relieved by strong opioid
therapy.10 Figure 1 demonstrates the interaction of THC
with the cannabinoid receptor on the presynaptic nerve.
Grade of pain perceived by patient rated 0-4 
Graph 1. Graph showing perceived pain before and after 
receiving cannabinoid therapy13
Cannabinoids have shown analgesic properties as seen in
graph 1. Along with analgesic properties, cannabinoids
can have anti-emetic and appetite inducing properties
which are beneficial in palliative treatments.9 These
properties all indicate that further research should be
carried out to assess the use of cannabinoids in
controlling chronic cancer pain in palliative patients. One
of the most interesting properties is cannabinoid’s opioid
sparing agents.9 This could potentially allow the opioid
dose to be reduced thereby reducing the side effects
associated with opioid use.
However side effects of cannabinoids can include
cognitive impairment, motor skill impairment, chronic
bronchitis, anxiety, psychosis and potential cardiovascular
toxicities.12 These toxicities indicate that further
investigation needs to be carried out before cannabinoids
could receive The National Institute for Health and Care
Excellence (NICE) approval.
The current practice for the management of palliative pain
in cancer patients is due for review. Rather than
employing evidence based practice current procedures
rely on familiarity and old studies to support the
continued use of opioids as first-line treatment.
Cannabinoids have very promising properties that can be
utilised in the treatment of chronic cancer pain in
palliative patients. With 60 active ingredients, including
those shown in figure 2, further research into the use of
cannabinoids could provide a suitable alternative to
opioids or produce a combination therapy.
Figure 2. Active components with 
potential analgesic properties.14
